A Phase 1 Dose-Escalation Study to Evaluate the Safety and Tolerability of HGS1029 (AEG40826-2HCl) in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2013
At a glance
- Drugs AEG 40826 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 30 Nov 2011 Planned end date changed from 1 Nov 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
- 26 Sep 2011 Planned end date changed from 1 Jun 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from recruiting to completed.